Designing Trust in Clinical Assay Development: How the Right Partner Supports Quality, Speed and Compliance
Introduction
Clinical diagnostic developers are under pressure. Teams are expected to move faster, meet rising regulatory expectations and deliver assays with robust performance across diverse samples and settings, all while managing cost and mitigating risk. Because of this pressure, every decision about assay design, validation, and manufacturing carries weight.
The choice of a development partner has become as critical as the technology itself. What makes a development partner trustworthy and reliable? What does an ideal clinical assay development partnership look like in practice?
Here, we explore these questions through three lenses: trust, collaboration, and alignment, drawing on the expertise of Dr. Alok Sharma, Global Director of the Clinical Market Segment (Promega). We look at how an integrated development model, grounded in rigorous quality systems and scientist-to-scientist collaboration, can help development teams bring assays to market with peace of mind. Our Clinical Assay Development Services (CADS) acts as a case study in how an ideal partnership works in practice, illustrating what effective collaboration can look like for diagnostic developers who need both reliability and flexibility.
Trust Grounded in Quality
In clinical assay development, trust should be established early. For many assay developers, trust rests on three pillars: transparent communication, validated technologies, and established quality systems.
A reliable partner builds in communication and checkpoints across the development process. In practice, this looks like transparent discussion of performance data, proactive identification of risks along with clear documentation of decisions, all while tailoring support to what each team already does well. As Alok puts it:
"[Developers] come in with different strengths. Some understand the whole process; others are seeing parts of it for the first time. Our job isn’t to judge that—it is to partner with them and lend expertise wherever it’s needed.”
Once expectations and roles are clear, the assay developer and development partner can shift to designing and testing the assay as a team. A clinical development partner will then validate and pressure-test the assay across a range of conditions (e.g. sample types, collection matrices and instruments) to ensure consistency and efficacy. Decisions about enzymes, detection chemistry and assay controls sit within a formal design framework and risk management process, so any hurdles are understood and addressed early. Both initial alignment and pressure testing shape the quality and consistency of the project at every stage of development.
Trust also depends on how the assay is made and supported over time. Consistent manufacturing and reliable supply rest on established quality systems and formal standards. Longstanding adherence to a globally recognized framework confirms that those systems are built to support safe, effective clinical products at scale. For CADS, that means adhering to ISO 9001:2015 for quality management systems, ISO 13485:2016 for medical devices, participation in the Medical Device Single Audit Program and alignment with In Vitro Diagnostic Regulation requirements. For assay developers, this improves lot-to-lot consistency, resolves documentation gaps and minimizes regulatory surprises. When an assay development partner can support both how the assay is built and how it is supplied, early trust in the relationship has a solid basis to carry through to routine clinical use.
Collaboration In A Scientist-To-Scientist Model
Imagine you are leading the development of a new clinical assay. Timelines are tight, but each decision—from assay format to application—has downstream implications. In this situation, assay development teams are looking for a collaborator who understands both the pressure and the technical demands of the work. Building on his earlier point about developers bringing different strengths to the table, Alok described how that shapes the way CADS works with assay developers:
"Many of the groups that come to us are very strong in R&D or they know their market well, but they haven’t necessarily taken a product all the way through commercialization. In those cases, our role is to fill the gaps—whether that’s commercialization, manufacturing or the R&D portion."
This is where the scientist-to-scientist model upgrades the assay development experience. Instead of communicating through layers of account management, our customers work directly with R&D scientists who live in the same world of experimental design and troubleshooting. Questions about signal stability or matrix effects become working sessions rather than tickets or long email chains.
For developers navigating complex clinical programs, that way of working matters as much as the underlying technology. Partnership shifts from a handoff model to aligned expertise at the bench. This alignment is anchored in a shared view of where the work is headed and how success is defined for the program. In Alok's words:
"We define success before we start the partnership. We want to know what success looks like for the [developer], what their strengths are and where they want to go before we even kick off the project."
Aligned From Concept to Launch
Decisions made during early stages of clinical assay development have consequences downstream. A development partner who understands that lifecycle can help keep work aligned through to implementation.
Flexibility and in-house control by the manufacturer play a central role in that alignment. When a single organization manages everything from reagent manufacturing through scale-up and validation within mature quality systems, integration becomes more straightforward. Additionally, teams can adjust formulations, formats or packaging with less risk of disrupting timelines. That integration supports speed to market, scalability and compliance with evolving standards by keeping scientific and operational decisions connected. Alok emphasized the value of this approach from a developer’s perspective:
"It helps to have a fully integrated partner that lets you pick and choose what parts of the process you want to work on together."
When both clinical assay developers and manufacturing partners work as an integrated team, there is less risk and more flexibility. An integrated pipeline can strengthen supply chain resilience because the critical components of assay development are already aligned.
For assay developers, strategic alignment ultimately results in peace of mind. A clinical assay development program that anticipates regulatory updates and is built around established manufacturing capabilities and supply stability is more likely to deliver a reliable, reproducible assay ready for clinical use.
Conclusion
A strong clinical assay development partnership is not defined by a single technology, it is defined by how trust, collaboration and alignment show up across the lifecycle of the assay. Our Clinical Assay Development Services team builds clear communication, sound assay performance and integrated manufacturing into each relationship. The end product is both a reliable assay and a trusted partner.